These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32004537)

  • 21. Drug Development 101: A Primer.
    Buckley LA; Bebenek I; Cornwell PD; Hodowanec A; Jensen EC; Murphy C; Ghantous HN
    Int J Toxicol; 2020; 39(5):379-396. PubMed ID: 32762387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.
    Gobburu JV; Marroum PJ
    Clin Pharmacokinet; 2001; 40(12):883-92. PubMed ID: 11735607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.
    Bolleddula J; Brady K; Bruin G; Lee A; Martin JA; Walles M; Xu K; Yang TY; Zhu X; Yu H
    Drug Metab Dispos; 2022 Jun; 50(6):837-845. PubMed ID: 35149541
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Jose J; S S; Mathew B; Parambi DGT
    Comb Chem High Throughput Screen; 2022; 25(12):1991-2000. PubMed ID: 34986768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classifying Free Texts Into Predefined Sections Using AI in Regulatory Documents: A Case Study with Drug Labeling Documents.
    Gray M; Xu J; Tong W; Wu L
    Chem Res Toxicol; 2023 Aug; 36(8):1290-1299. PubMed ID: 37487037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore.
    Haqaish WSA; Obeidat H; Patel P; Walker S
    Pharmaceut Med; 2017; 31(1):21-30. PubMed ID: 28572733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health.
    Molzon JA; Giaquinto A; Lindstrom L; Tominaga T; Ward M; Doerr P; Hunt L; Rago L
    Clin Pharmacol Ther; 2011 Apr; 89(4):503-12. PubMed ID: 21326288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.
    Leighton JK; Brown P; Ellis A; Harlow P; Harrouk W; Pine PS; Robison T; Rosario L; Thompson K
    Environ Health Perspect; 2006 Apr; 114(4):573-8. PubMed ID: 16581548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
    Kajiwara E; Shikano M
    Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electronic common technical document submission with analysis using R.
    Zhao Y; Xiao N; Anderson K; Zhang Y
    Clin Trials; 2023 Feb; 20(1):89-92. PubMed ID: 36169229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA pharmaceutical quality oversight.
    Yu LX; Woodcock J
    Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistics, Quality Review Issues, and Beyond for Generic Drug Applications in Taiwan.
    Chang LC; Gau CS
    Ther Innov Regul Sci; 2013 Nov; 47(6):670-677. PubMed ID: 30235552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.